Skip to content
OpenCapital
Get started

Fortress Biotech FBIO Q4 2025 Annual earnings

Reported March 31, 2026 · After market close

Revenue$16.1MMiss by $10.1MDiluted EPS-$0.21Miss by $0.63
Revenue estimate$26.2M
EPS estimate$0.42

Next report

Aug 13, 2026 (in a month)
Revenue estimate$18.3M
EPS estimate-$0.20

Versus estimates

Revenue

Q1 2026$16.0MMiss by $300.0K
Q4 2025$16.1MMiss by $10.1M
Q3 2025$17.6MMiss by $3.4MQ2 2025$16.4MMiss by $4.6MQ1 2025$13.1MBeat by $1.5MQ4 2024$15.1MMiss by $1.2M

Diluted EPS

Q1 2026$2.82Beat by $3.04
Q4 2025-$0.21Miss by $0.63
Q3 2025$0.11Beat by $0.54Q2 2025-$0.46Miss by $0.15Q1 2025-$1.03Miss by $0.59Q4 2024-$0.53Beat by $0.26

Ask the moment Fortress Biotech reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Fortress Biotech report Q4 2025 earnings?
Fortress Biotech (FBIO) reported Q4 2025 earnings on March 31, 2026 after market close.
What were Fortress Biotech's Q4 2025 revenue and EPS?
Fortress Biotech reported revenue of $16.1M and diluted EPS of $-0.21 for Q4 2025.
Did Fortress Biotech beat estimates in Q4 2025?
Revenue missed the consensus estimate of $26.2M by $10.1M. EPS missed the consensus estimate of $0.42 by $0.63.
How did Fortress Biotech's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 6.4% from $15.1M a year earlier and diluted EPS grew 60.4% from $-0.53.
Where can I find Fortress Biotech's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-036818) and the 10-K periodic report (0001104659-26-037874) directly on SEC EDGAR. The filing index links above go to sec.gov.